• AngioDynamics (Queensbury, New York) introduced its Smart Port CT at the 32nd annual scientific meeting of the Society of Interventional Radiology being held in Seattle. The new vascular access port is indicated for power injection of contrast media with a flow rate of 5mL/sec. Initial shipments are expected during the company’s fiscal fourth quarter. In a clinical trial comparing the Vortex technology to conventional ports, the Vortex had a 7% occlusion rate compared with a 26% occlusion rate for conventional ports.

• Cytomyx (Cambridge, UK) reported that it has launched new biomarker tools from its earlier collaboration with OriGene Technologies (Rockville, Maryland). Cytomyx supplied hundreds of highly characterized RNA samples from a wide range of major cancers from its extensive Biorepository. OriGene has used these samples to develop human tissue Real-Time PCR Panels. The panels currently cover prostate, breast, colon, lung, ovarian, thyroid and kidney cancers allowing scientists to validate biomarkers across hundreds of tissues in less than two hours. Each unique tissue is linked to “highly annotated” pathology reports and tissue images. The TissueScan Panels are designed to enable researchers to profile gene expression levels in these patient derived samples to determine linkages between gene expression and tumor occurrence and development.

• Epocrates (San Mateo, California) reported the launch of two new mobile applications to provide clinical information at the point of care. The ICD-9/CPT reference helps clinicians identify diagnostic and procedural billing codes, while the medical dictionary enables users to reference over 100,000 medical terms. Physicians receive financial reimbursement based on designated diagnostic (ICD-9) and procedural (CPT) codes. The Epocrates allows clinicians to access over 20,000 routinely updated ICD-9 and CPT billing codes. Instant access to these codes at the point of care can help clinicians more accurately identify the appropriate codes needed for service reimbursement. The Epocrates medical dictionary allows healthcare professionals to quickly access medical terms and eponyms on their mobile devices.

• Focus Diagnostics (Cypress, California) reported receiving FDA 510(k) clearance for its Plexus HerpeSelect 1 and 2 IgG test kit, which uses multiplex type-specific HSV serology panel using xMAP technology from Luminex. The test kit provides laboratories with a complete HSV serology profile from a single specimen, in a single assay, using Luminex instrumentation. Laboratories that have a Luminex instrument system in place can expand their test menu to include the HerpeSelect 1 and 2 serology panel. The Plexus assay uses glycoprotein G — gG1 and gG2 — the antigens corresponding to HSV-type 1 and 2, respectively. The Luminex xMAP technology uses laser optics similar to flow cytometry and an array of fluorescent dye-labeled beads to simultaneously detect multiple targets in the same specimen. Focus Diagnostics, a wholly owned subsidiary of Quest Diagnostics, is an infectious disease diagnostics company.

• Nanogen (San Diego) reported that it has been issued four patents by the U.S. Patent and Trademark Office for inventions related to diabetes and Alzheimers disease biomarkers. The patents are the most recent in a series describing biomarkers associated with these diseases. U.S. Patent No. 7,179,610, “Complement C3 precursor biopolymer markers indicative of insulin resistance,” and U.S. Patent No. 7,132,244, “Betaine/GABA transport protein biopolymer marker indicative of insulin resistance,” describe the use of mass spectrometry and time-of-flight detection techniques to identify biopolymers that could potentially be used in the diagnosis of or development of therapeutics for the metabolic conditions Syndrome X and type II diabetes. U.S. Patent No. 7,179,605, “Fibronectin precursor biopolymer markers indicative of Alzheimer’s disease,” and U.S. Patent No. 7,179,606, “IG heavy chain, IG kappa, IF lambda biopolymer markers indicative of Alzheimer’s disease,” relate to the identification of protein biomarkers for Alzheimer’s disease.

• Zonare Medical Systems (Mountain View, California) reported the introduction of the z.one ultra system, the next generation in Zone Sonography technology for what the company said is the first Convertible Ultrasound platform at the Society of Interventional Radiology conference that began Thursday and continues through today in Seattle. The new z.one ultra system uses Zone Sonography technology, building upon the precedence set by the first z.one system. Zonare makes compact sonography devices.

No Comments